Hospital Acquired Infection Treatment Market Size and Forecast (2020–2030), Global and Regional Share, Trends, and Growth Opportunity Analysis
Coverage: Drug Class (Antibacterial Drugs, Antiviral Drugs, Antifungal Drugs, and Others), Infection Type (Urinary Tract Infections, Ventilator-associated Pneumonia, Surgical Site Infections, Bloodstream Infections, and Other Hospital Infections), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, E-Commerce, and Others), and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)
Avail Sample PDF Copy @ https://www.theinsightpartners.com/sample/TIPRE00029976/
Hospital Acquired Infection Treatment Market: Geographical Overview
Asia Pacific is estimated to register the highest CAGR from 2022 to 2030. Countries in the Asia Pacific, such as India and China, hold significant potential for the hospital-acquired infection treatment market growth. Developing countries in the region with improving healthcare infrastructure, increasing healthcare expenditure, and a rising focus on adopting advanced medical technologies offer opportunities for market expansion.
In 2022, North America held the largest share of the global hospital-acquired infection treatment market. The US has a high prevalence of HAI, which propels the hospital-acquired infection treatment market growth. As per the CDC, on any given day, about 1 in 31 hospital patients has at least one HAI. Similarly, according to the Office of Disease Prevention and Health Promotion, HAIs and other infections can lead to sepsis, and it causes 1.7 million illness cases and 270,000 deaths per year in the US. Thus, the high prevalence of HAI among people in the US fuels the hospital-acquired infection treatment market growth.
Hospital Acquired Infection Treatment Market: Segmental Overview
The hospital acquired infection treatment market, by drug class, is segmented into antibacterial, antiviral, antifungal, and others. The antibacterial drugs segment held the largest market share in 2022 and is anticipated to register the highest CAGR during 2022–2030.
The hospital acquired infection treatment market, by infection type, is segmented into urinary tract infections, ventilator-associated pneumonia, surgical site infections, bloodstream infections, and other hospital infections. The urinary tract infections segment held the largest market share in 2022. However, the ventilator-associated pneumonia segment is anticipated to register the highest CAGR from 2022 to 2030.
The hospital acquired infection treatment market, by distribution channel, is segmented into hospital pharmacies, retail pharmacies, e-commerce, and others. In 2022, the hospital pharmacies segment held the largest market share, and the same segment is anticipated to register the highest CAGR during 2022–2030.
The Insight Partners is a market research solution and consultation company. Specializing in syndicate market research, our team helps clients in their hunt for revenue pockets in several industries. A team of 250+ research experts is dedicated to offering the most relevant, data-driven, and trustworthy market insights and consultation.
Contact Us:
If you have any queries about this report or if you would like further information, please contact us
The Insight Partners
Phone: +1-646-491-9876
E-mail: [email protected]
